alphamab oncology ( is included in the hang seng composite index-凯发88

english 中文简体 中文繁体

alphamab oncology ( is included in the hang seng composite index

august 18, 2020 11:00 eastern daylight time

recently, hang seng indexes company limited announced the results of the quarterly review of the hang seng index series as of june 30, 2020. alphamab oncology ( has been included in the hang seng composite index and will take effect on september 7, 2020 (monday).

the hang seng composite index (“hsci”) offers a comprehensive hong kong market benchmark that covers about the top 95th percentile of the total market capitalisation of companies listed on the main board of the stock exchange of hong kong (“sehk”). adopting the freefloat-adjusted market capitalization methodology, the hsci can be used as a basis for index funds, mutual funds as well as performance benchmarks. it reflects the company's market value, stock circulation, business performance and financial status and other indicators have reached a high level. alphamab oncology’s inclusion in the hang seng composite index reflected the capital market’s further recognition of alphamab oncology’s business performance and future growth prospects, which will help to enhance the company’s influence in the capital market.

about alphamab oncology

alphamab oncology is a biopharmaceutical company focusing on innovative biologics medicine in oncology. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.

alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into phase i – iii clinical development phases in china, us and japan.  

the company also has state-of-the-art manufacturing capability designed and built to meet nmpa and eu/fda’s cgmp standards. alphamab oncology is committed to further develop its robust pipeline in oncology/immunology to benefit patients around the world.

visit for more information.

alphamab oncology forward-looking statements

this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.